Targeting ABCA1 and ABCG1 to regulate cholesterol efflux in MCE pathways is a promising strategy.While reduced ABCA1 expression alone is not enough to induce DKD, experimental manipulation through genetic or pharmacological means to increase ABCA1 levels has shown promising results in mitigating kidney disease progression, indicating ABCA1 as a potential target for therapeutic intervention. This evidence concerns the gene ABCG1 and diabetic kidney disease.